My 2014 interview with on The Jordan Rich Show; shared my concern about lack of awareness about #healthdisparities and lack of access back then. Six years later, folks are shocked by #COVID data. #CanYouHearMeNow?
https://t.co/tjQzOtKqLk
The lack of difference w/wo histological confirmation is reassuring. However, I'm even more intrigued by the absolute median OS value which is very close to surgical series. @HoudaBahig @b_fischervaluck @DrAlexLouie#radonc#lcsm
The new ESTRO Presidency (2020-2022) starts today! Ben Slotman as President, Umberto Ricardi as past President, and Anna Kirby as President-elect #radonc
Congratulations to Anna for her election. Thanks to Yolande Lievens for her leadership over the past 6 years.
#womenwhocurie
ASTRO-ESTRO head and neck guidelines for COVID19!
Included are case studies with Delphi consensus for recommendations, hypofractionation, chemotherapy, and what to do when surgery is limited
https://t.co/u9rViBN4Fh
New prostate hypofx constraints for rectum have been provided by the CHHiP team based on case controlled toxicity outcomes. This is about the best level data one can ask for. Added to the oral boards sheet: https://t.co/0PPQHTMhqa Paper: https://t.co/MLk8EOSVyK
What can you do to reduce your cancer risk? Be active 🏃♂️, choose healthy foods 🍎, quit smoking 🚭, and more! #WorldCancerDay#IAmAndIWill https://t.co/yqrOIoDN7X
Have you heard about Google investing in medical technology? They're using #AI to improve the accuracy of mammogram readings. Learn more: https://t.co/nmsGrn6zsa #oncology#cancercare#tech#innovation#breastcancer
ASTRO has published guidelines for cutaneous SCC/BCC. There are some difference from NCCN, namely that ASTRO recommends adjuvant RT for T3, T4, and close margins in SCC and NCCN does not. On my review, there is low quality evidence. 1/2
Your radiation oncologist will discuss the benefits and risks of #radiationthearpy. In many cases, your #cancer will be treated using more than one type of treatment. Learn more about #radiation treatment here: https://t.co/vfXQYMgKVj #RadOnc
There is no agreed-upon definition on the term "oligometastatic #NSCLC" - particularly on the upper limit of lesions that qualify to be labeled as such. We've published two papers (https://t.co/fAkmZ2rUfy, https://t.co/hvC6T8RDJw) that explore this important topic. #LCSM
#ICYMI: A new ASTRO-sponsored survey of #patients treated with #radiationtherapy points to gaps in #patient counseling and informed consent processes: https://t.co/unETacW9T1
Weekend Reading: From the masters Daniel Golman and @RBoyatzis in @HarvardBiz: The 4 domains and 12 competencies of EI. Most importantly, these are "learnable capabilities that allow outstanding performance at work or as a leader" https://t.co/uB1nLbcDCv ⬇️
Paul Upperman was diagnosed in 2018 at the age of 44 with bone and stage IV #ProstateCancer. Read Paul’s story of survivorship in the new #patient story here: https://t.co/crOWToMfY5 #PCSM